India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru ...

Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...

CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...

Biocon share price surged 4.5% during Monday's session following the clearance from the US Food and Drug Administration (US ...

Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...